XLRN - Acceleron Pharma Inc...About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $100.68 | Open | $100.53 |
| Volume | 305.4K | Market Cap | 5.909B |
| Yield | Last Dividend |
| Acceleron Announces Pricing of Public Of... | 06/30/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commer... | |
| Acceleron readies $400M stock offering (... | 06/29/20 |
| Acceleron Pharma (NASDAQ:XLRN) initiates a $400M public offering of common stock. Price, volume and terms have yet to be announced. | |
| Acceleron Announces Proposed Public Offe... | 06/29/20 |
| Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development and commercialization of TGF-beta superfamily | |
| The Daily Biotech Pulse: MediciNova On T... | 06/24/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) ACA... | |
| Acceleron to Host Conference Call and We... | 06/22/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commer... | |
| Acceleron (XLRN) Down 6.2% Since Last Ea... | 06/10/20 |
| Acceleron (XLRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| Acceleron Appoints Christopher Hite to i... | 06/04/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commerc... | |
| Acceleron Announces Oral Presentation of... | 05/19/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and comm... | |
| Acceleron Announces Publication in Scien... | 05/13/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and comm... | |
| The Daily Biotech Pulse: Gilead Signs Ma... | 05/13/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Acce... | |
| Acceleron (XLRN) Q1 Loss Wider Than Expe... | 05/12/20 |
| Acceleron (XLRN) posts a wider-than-expected Q1 loss due to increased operating expenses. The company misses on revenues as well. | |
| Acceleron Pharma (XLRN) Reports Q1 Loss,... | 05/11/20 |
| Acceleron (XLRN) delivered earnings and revenue surprises of -13.10% and -21.02%, respectively, for the quarter ended March 2020. Do the numbers hold ... | |
| Acceleron Reports First Quarter 2020 Ope... | 05/11/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and comme... | |
| The Daily Biotech Pulse: Ayala IPO, Plur... | 05/08/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 7) ??? A... | |
| Acceleron to Webcast First Quarter 2020 ... | 05/05/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Monday, May 11, 2... | |
| 3 Keros Analysts On Why Biopharma Is A C... | 05/04/20 |
| Keros Therapeutics Inc (NASDAQ: KROS ), a clinical-stage biopharma focused on the development of treatments for rare hematologic and musculoskeletal d... | |
| Acceleron Receives Priority Medicines (P... | 05/04/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and comm... | |
| Acceleron Announces Retirement of Direct... | 04/07/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and comme... | |
| Acceleron Receives Thumbs Up From Street... | 04/06/20 |
| Acceleron (XLRN) has received U.S. The post Acceleron Receives Thumbs Up From Street On FDA Reblozyl Label Expansion appeared first on Smarter Analyst... | |
| The Week Ahead In Biotech: Clinical Read... | 03/29/20 |
| After starting the week ended March 28 on the backfoot, biotech stocks recovered through the week. Activity in the space remained light, although coro... | |
| The Daily Biotech Pulse: Takeda Jumps In... | 03/04/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 3) ... | |
| Acceleron Reports Fourth Quarter and Ful... | 02/27/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and comm... | |
| Acceleron to Participate in Two Upcoming... | 02/26/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-be... | |
| Acceleron Pharma (XLRN) May Report Negat... | 02/20/20 |
| Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with... | |
| Acceleron to Webcast Fourth Quarter and ... | 02/18/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, Februar... | |
| The Daily Biotech Pulse: J&J Intensifies... | 02/12/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) ... | |
| The Daily Biotech Pulse: Assertio To Sel... | 02/07/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 6) A... | |
| The Daily Biotech Pulse: Merck Spins Off... | 02/05/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 4) A... | |
| The Daily Biotech Pulse: EyePoint In-Lic... | 02/04/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 3.) Ac... | |
| The Daily Biotech Pulse: Novartis Earnin... | 01/29/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 28) ... | |
| Strong Buy rating | 06/26/20 |
| SVB Leerink maintains Outperform rating and raises Price Target from $127.00 to $132.00 | |
| Strong Buy rating | 06/25/20 |
| Credit Suisse maintains Outperform rating and raises Price Target from $123.00 to $134.00 | |
| Buy rating | 06/02/20 |
| Citigroup maintains Buy rating and raises Price Target from $136.00 to $137.00 | |
| Strong Buy rating | 05/12/20 |
| Oppenheimer maintains Outperform rating and raises Price Target from $112.00 to $115.00 | |
| Strong Buy rating | 05/12/20 |
| JP Morgan maintains Overweight rating and raises Price Target from $108.00 to $118.00 | |
| Strong Buy rating | 05/08/20 |
| Credit Suisse maintains Outperform rating and raises Price Target from $99.00 to $123.00 | |
| Date | 2020-05-11 (AMC) | Est. (EPS/Rev.) | ($0.86)/ 5.26M |
| Actual (EPS/Rev.) | $-0.95/ $4.34 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
